hrcak mascot   Srce   HID

Pregledni rad

TREATMENT OF ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY RELATED VASCULITIS

Krešimir Galešić
Ivica Horvatić

Puni tekst: hrvatski, pdf (237 KB) str. 0-0 preuzimanja: 106* citiraj
APA 6th Edition
Galešić, K. i Horvatić, I. (2014). LIJEČENJE VASKULITISA POVEZANIH S ANTINEUTROFILNIM CITOPLAZMATSKIM PROTUTIJELIMA. Liječnički vjesnik, 136 (7-8), 0-0. Preuzeto s https://hrcak.srce.hr/172625
MLA 8th Edition
Galešić, Krešimir i Ivica Horvatić. "LIJEČENJE VASKULITISA POVEZANIH S ANTINEUTROFILNIM CITOPLAZMATSKIM PROTUTIJELIMA." Liječnički vjesnik, vol. 136, br. 7-8, 2014, str. 0-0. https://hrcak.srce.hr/172625. Citirano 19.10.2019.
Chicago 17th Edition
Galešić, Krešimir i Ivica Horvatić. "LIJEČENJE VASKULITISA POVEZANIH S ANTINEUTROFILNIM CITOPLAZMATSKIM PROTUTIJELIMA." Liječnički vjesnik 136, br. 7-8 (2014): 0-0. https://hrcak.srce.hr/172625
Harvard
Galešić, K., i Horvatić, I. (2014). 'LIJEČENJE VASKULITISA POVEZANIH S ANTINEUTROFILNIM CITOPLAZMATSKIM PROTUTIJELIMA', Liječnički vjesnik, 136(7-8), str. 0-0. Preuzeto s: https://hrcak.srce.hr/172625 (Datum pristupa: 19.10.2019.)
Vancouver
Galešić K, Horvatić I. LIJEČENJE VASKULITISA POVEZANIH S ANTINEUTROFILNIM CITOPLAZMATSKIM PROTUTIJELIMA. Liječnički vjesnik [Internet]. 2014 [pristupljeno 19.10.2019.];136(7-8):0-0. Dostupno na: https://hrcak.srce.hr/172625
IEEE
K. Galešić i I. Horvatić, "LIJEČENJE VASKULITISA POVEZANIH S ANTINEUTROFILNIM CITOPLAZMATSKIM PROTUTIJELIMA", Liječnički vjesnik, vol.136, br. 7-8, str. 0-0, 2014. [Online]. Dostupno na: https://hrcak.srce.hr/172625. [Citirano: 19.10.2019.]

Sažetak
ANCA-associated vasculitides are a well-known clinico-pathological group of systemic diseases comprising microscopic poliangiitis, granulomatosis with poliangiitis and eosinophilic granulomatosis with poliangiitis. This article shows contemporary treatment of this diseases with extensive literature review. Stepwise treatment of ANCA-associated vasculitides is divided into induction therapy and remission maintenance therapy. Standard induction therapy is a combination of glucocorticoids and cyclophosphamide, and in maintenance therapy, combination of low-dose glucocorticoids and azathioprine or methotrexate is used. Leading rheumatology and nephrology associations developed treatment guidelines. Since ANCA-associated vasculitides are relatively rare diseases, there are only few randomized controlled studies to provide high level of evidence and treatment recommendations. Most patients achieve remission, but relapses often occur. The main treatment considerations, apart from frequently relapsing disease, are disease refractory to treatment and potentially harmful effects of immunosuppressants, especially cyclophosphamide. Future studies are needed to determine the effects of less toxic immunosuppressants, mainly biological agents.

Ključne riječi
Anti-neutrophil cytoplasmic antibody-associated vasculitis – diagnosis, drug therapy; Glucocorticoids – therapeutic use, administration and dosage; Cyclophosphamide – therapeutic use, administration and dosage, adverse effects; Immunosuppressive agents – therapeutic use, administration and dosage, adverse effects; Antibodies, monoclonal, murine-derived – therapeutic use; drug therapy, combination; recurrence

Hrčak ID: 172625

URI
https://hrcak.srce.hr/172625

[hrvatski]

Posjeta: 189 *